Interesting facts
Exploring 5-Methyl-2,5-diazatetracyclo[13.4.0.02,7.08,13]nonadeca-1(19),8,10,12,15,17-hexaene
5-Methyl-2,5-diazatetracyclo[13.4.0.02,7.08,13]nonadeca-1(19),8,10,12,15,17-hexaene is a fascinating compound that offers profound insights into the world of organic and heterocyclic chemistry. Here are some interesting facts to consider:
- Unique Structure: This compound features a complex polycyclic structure that includes multiple nitrogen atoms, showcasing the interplay of various chemical bonding interactions.
- Potential Applications: Compounds with similar frameworks are often investigated for their potential uses in pharmaceuticals, especially in the development of novel medications.
- Conjugated Systems: The presence of a hexatriene motif indicates that the compound could exhibit interesting electronic properties, potentially making it useful in organic electronics or photonics.
- Synthetic Challenges: The synthesis of such intricate structures can pose significant challenges, requiring advanced synthetic techniques and a deep understanding of reaction mechanisms.
- Research Interest: The unique combination of heteroatoms and cyclical systems promises ongoing research opportunities in fields such as material science and medicinal chemistry.
In the words of pioneering chemist Linus Pauling, “The best way to have a good idea is to have lots of ideas.” This compound embodies that philosophy, presenting a landscape filled with possibilities and the promise of discovery in the exciting realm of chemistry.
Synonyms
mianserin
Mianserine
24219-97-4
Mianserina
Mianseryna [Polish]
Mianserinum
Mianseryna
Tolvon
Mianserine [INN-French]
Mianserinum [INN-Latin]
Mianserina [INN-Spanish]
Norval
Mianserin [INN:BAN]
Mianserin (INN)
Tolvon (TN)
(+/-)-Mianserin
1,2,3,4,10,14b-Hexahydro-2-methyldibenzo(c,f)pyrazino(1,2-a)azepine
CHEBI:51137
HSDB 7182
EINECS 246-088-6
UNII-250PJI13LM
2-Methyl-1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino[1,2-a]azepine
BRN 0755346
250PJI13LM
DTXSID6023317
MIANSERIN [INN]
MIANSERIN [MI]
MIANSERIN [HSDB]
MIANSERIN [VANDF]
MIANSERIN [WHO-DD]
CHEMBL6437
Dibenzo(c,f)pyrazino(1,2-a)azepine, 1,2,3,4,10,14b-hexahydro-2-methyl-
J16.389I
DTXCID003317
Dibenzo[c,f]pyrazino[1,2-a]azepine, 1,2,3,4,10,14b-hexahydro-2-methyl-
NCGC00015656-06
Mianserine (INN-French)
Mianserinum (INN-Latin)
Mianserina (INN-Spanish)
Mianserin Monohydrochloride
5-methyl-2,5-diazatetracyclo[13.4.0.0^{2,7}.0^{8,13}]nonadeca-1(15),8(13),9,11,16,18-hexaene
5-methyl-2,5-diazatetracyclo[13.4.0.0^{2,7}.0^{8,13}]nonadeca-1(19),8,10,12,15,17-hexaene
1,2,3,4,10,14b-hexahydro-2-methyldibenzo[c,f]pyrazino[1,2-a]azepine
1,2,3,4,10,14B-HEXAHYDRO-2-METHYLDIBENZO(C,F)-PYRAZINO(1,2-A)AZEPINE
5-methyl-2,5-diazatetracyclo[13.4.0.02,7.08,13]nonadeca-1(19),8,10,12,15,17-hexaene
(S)-(+)-Mianserin
CAS-24219-97-4
Monohydrochloride, Mianserin
mianserin a
Mianserin?
5-methyl-2,5-diazatetracyclo(13.4.0.0^(2,7).0^(8,13))nonadeca-1(15),8(13),9,11,16,18-hexaene
5-methyl-2,5-diazatetracyclo(13.4.0.0^(2,7).0^(8,13))nonadeca-1(19),8,10,12,15,17-hexaene
S(+)-Mianserin
(+-)-Athymil
Spectrum_001810
PS32 - Mianserin
Prestwick0_000099
Prestwick1_000099
Prestwick2_000099
Prestwick3_000099
Spectrum2_001203
Spectrum3_001836
Spectrum4_001260
Spectrum5_001772
Biomol-NT_000135
Lopac0_000744
Oprea1_703627
SCHEMBL18020
BSPBio_000058
BSPBio_003511
GTPL135
KBioGR_001820
KBioSS_002303
DivK1c_000844
SPBio_000986
SPBio_001997
BPBio1_000064
BPBio1_000331
KBio1_000844
KBio2_002301
KBio2_004869
KBio2_007437
KBio3_003016
N06AX03
NINDS_000844
HMS2089A04
BCA15288
HY-B0188
Tox21_110191
AC-631
BDBM50222218
PDSP1_001532
PDSP2_001516
AKOS005216268
Tox21_110191_1
CCG-204829
CS-2078
DB06148
SDCCGSBI-0050722.P004
IDI1_000844
NCGC00015656-04
NCGC00015656-05
NCGC00015656-08
NCGC00015656-09
NCGC00015656-10
NCGC00015656-12
NCGC00015656-23
NCGC00024926-03
NCGC00024926-04
DA-65446
TS-08152
SBI-0050722.P003
NS00010650
1,2,3,4,10,14b-Hexahydro-2-methyldibenzo
D08216
EN300-18559884
L000736
Q416701
2-Methyl-1,2,3,4,10,14b-hexahydro-2H-pyrazino
BRD-A19661776-001-01-5
BRD-A19661776-003-05-2
BRD-A19661776-003-16-9
BRD-A19661776-003-25-0
BRD-A19661776-003-26-8
BRD-A19661776-003-27-6
BRD-A19661776-003-28-4
2-Methyl-1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino[1,2-a]azepine #
246-088-6
Dibenzo[c,f]pyrazino[1,2-a]azepine, 1,2,3,4,10,14b-hexahydro-2-methyl-; 1,2,3,4,10,14b-Hexahydro-2-methyldibenzo[c,f]pyrazino[1,2-a]azepine; (+/-)-Mianserin; Mianserin; Mianserine
Solubility of 5-methyl-2,5-diazatetracyclo[13.4.0.02,7.08,13]nonadeca-1(19),8,10,12,15,17-hexaene
The solubility of 5-methyl-2,5-diazatetracyclo[13.4.0.02,7.08,13]nonadeca-1(19),8,10,12,15,17-hexaene (C18H19ClN4) presents an intriguing study due to its complex molecular structure. Typically, the solubility of such nitrogen-containing compounds can be influenced by several factors:
In practical applications, it is essential to note that the solubility profile may vary depending on the solvent used:
Therefore, determining the precise solubility requires thorough experimental evaluation, as "one size does not fit all" when it comes to solvents and solubility characteristics. Understanding these aspects is critical for applications related to pharmacology and synthesis in organic chemistry.